Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: Application to midazolam and a phase i compound. Part 1: Comparison of uniresponse and multiresponse designs using PopDes

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 35, Issue 6, 2008, Pages 635-659

  Chenel, Marylore ^a   Bouzom, François ^a   Aarons, Leon ^b   Ogungbenro, Kayode ^b  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Drug drug interaction; Midazolam; Multiresponse; Non linear mixed effects models; Optimal experimental design; Physiologically based pharmacokinetic models

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; MIDAZOLAM; SX; UNCLASSIFIED DRUG; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; ENZYME INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; NORMAL HUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; BIOLOGICAL MODEL; COMPARATIVE STUDY; COMPUTER SIMULATION; DRUG ANTAGONISM; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PREDICTION AND FORECASTING; TIME;

CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MIDAZOLAM; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; TIME FACTORS;

EID: 64149107347     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-008-9104-6     Document Type: Article

References (38)

1. M Rowland L Balant C Peck 2004 Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002) AAPS PharmSci 6 1 E6 E12 10.1208/ps060106
2. FP Theil TW Guentert S Haddad P Poulin 2003 Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection Toxicol Lett 138 1-2 29 49 10.1016/S0378-4274(02)00374-0
3. HM Jones N Parrot K Jorga T Lavé 2006 A novel strategy for physiologically based predictions of human pharmacokinetics Clin Pharmacokinet 45 5 511 542 10.2165/00003088-200645050-00006
4. K Krishnan HJ Clewell III ME Andersen 1994 Physiologically based pharmacokinetic analyses of simple mixtures Environ Health Perspect 102 Suppl 9 151 155
5. R Tardif G Charest-Tardif J Brodeur K Krishnan 1997 Physiologically based pharmacokinetic modelling of ternary mixture of alkyl benzenes in rats and humans Toxicol Appl Pharmacol 144 120 134 10.1006/taap.1996.8096
6. Ozdemir MCK, Tucker GT Rostami-Hodjegan A (2006) The impact of ketoconazole dosage regimen on midazolam clearance and its prediction using PBPK modelling. Eur J Pharm Sci (in press): Abstract of the European Federation for Pharmaceutical Sciences Conference on optimising drug development together with Biosim EU network of excellence, Basel, Switzerland, 29 Nov-1 Dec 2006
7. M Vossen M Sevestre C Niederalt 2007 Dynamically simulating the interaction of Midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models Theor Biol Med Model 4 13 10.1186/1742-4682-4-13
8. MK Al-Banna AW Kelman B Whiting 1990 Experimental design and efficient parameter estimation in population pharmacokinetics J Pharmacokinet Biopharm 18 347 360 10.1007/BF01062273
9. EN Jonsson R Wade MO Karlsson 1996 Comparison of some practical sampling strategies for population pharmacokinetic studies J Pharmacokinet Biopharm 24 245 263 10.1007/BF02353491
10. Mentré F, Dufful S, Gueorguieva I, Hooker A, Leonov S, Ogungbenro K, Retout S (2007) Software for optimal design in population pharmacokinetics and pharmacodynamics: a comparison. ISSN 1871-6032, p 16, Abstract 1179
11. I Gueorguieva K Ogungbenro G Graham S Glatt L Aarons 2007 A program for individual and population optimal design for univariate and multivariate response pharmacokinetic and pharmacodynamic models Comput Methods Programs Biomed 86 1 51 61 10.1016/j.cmpb.2007.01.004
12. acslXtreme, Aegis Technology, Huntsville, USA
13. S Björkman 2001 Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model J Pharm Sci 90 9 1226 1241 10.1002/jps.1076
14. T Rodgers D Leahy M Rowland 2005 Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases J Pharm Sci 94 6 1259 1276 10.1002/jps.20322
15. T Rodgers D Leahy M Rowland 2005 Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat J Pharm Sci 94 6 1237 1248 10.1002/jps.20323
16. Gibaldi M, Perrier D (1982) Drugs and the pharmaceutical sciences. Pharmacokinetics (Volume 15). Second edition. Marcel Dekker, Inc. New York, Basel
17. EPA report (1988) Reference physiological parameters in pharmacokinetic modeling. EPA/600/6-88/004
18. B Ploeger T Mensinga A Sips J Meulenbelt J DeJongh 2000 A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling Pharm Res 17 12 1516 1525 10.1023/A:1007661209921
19. XL Yu JR Crison GL Amidon 1996 Compartmental transit and dispersion model analysis of small intestinal transit flow in humans Int J Pharm 140 1 111 118 10.1016/0378-5173(96)04592-9
20. J Yang M Jamei K Rowland Yeo GT Tucker A Rostami-Hodjegan 2007 Prediction of intestinal first-pass drug metabolism Curr Drug Metab 8 676 684 10.2174/138920007782109733
21. SimCYP version 7, SimCYP Ltd, Sheffield, UK
22. L Von Moltke 1996 Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, nofluoxetine and by azole antifungal agents J Clin Pharmacol 36 9 783 791
23. SR Poulter 1998 Monte Carlo simulation in environmental risk assessment-science, policy and legal issues. RISK: health Saf Environ 9 7 26
24. Beal SL, Sheiner LB (1996) NONMEM users guides, version 5, NONMEM project group. University of California, San Francisco
25. S Retout F Mentré R Bruno 2002 Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics Stat Med 21 18 2623 2639 10.1002/sim.1041
26. F Mentré Y Burtin Y Merle J Van Bree A Mallet J-L Steimer 1995 Sparse- sampling optimal designs in pharmacokinetics and toxicokinetics Drug Inf J 29 997 1019
27. F Mentré A Mallet D Baccar 1997 Optimal design in random-effects regression models Biometrika 84 429 442 10.1093/biomet/84.2.429
28. M Tod F Mentré Y Merle A Mallet 1998 Robust optimal design for the estimation of hyperparameters in population pharmacokinetics J Pharmacokinet Biopharm 26 689 716 10.1023/A:1020703007613
29. S Retout SB Duffull F Mentré 2001 Development and implementation of the population Fisher information matrix for evaluation of population pharmacokinetic designs Comput Methods Programs Biomed 65 2 141 151 10.1016/S0169-2607(00)00117-6
30. SB Duffull F Mentré L Aarons 2001 Optimal design of a population pharmacodynamic experiment for ivabradine Pharm Res 18 1 83 89 10.1023/A:1011035028755 Erratum in: Pharm Res (2003) 20(2):333
31. M Chenel K Ogungbenro V Duval C Laveille R Jochemsen L Aarons 2005 Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial J Pharmacokinet Pharmacodyn 32 5-6 737 756 10.1007/s10928-005-0014-6
32. K Ogungbenro I Gueorguieva G Grahams L Aarons 2005 The use of a modified Fedorov exchange algorithm in optimising sampling times for population pharmacokinetic experiments Comput Methods Programs Biomed 80 2 115 125 10.1016/j.cmpb.2005.07.001
33. Fedorov VV (1972) Theory of experiments. Academic Press, New York
34. KT Olkkola JT Backman PJ Neuvonen 1994 Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole Clin Pharmacol Ther 55 5 481 485
35. CB Eap T Buclin G Cucchia 2004 Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity Eur J Clin Pharmacol 60 237 246
36. L Pronzato 2002 Information matrices with random regressors. Application to experimental designs J Stat Plann Inferenece 108 189 200 10.1016/S0378- 3758(02)00278-1
37. EI Ette AW Kelman AC Howie B Whiting 1993 Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters Ann Pharmacother 27 1034 1039
38. F Mentré C Dubruc JP Thenot 2001 Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution on children J Pharmacokinet Pharmacodyn 28 3 299 319 10.1023/A:1011583210549